Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

A Boost in Mitochondrial Activity Underpins the Cholesterol-Lowering Effect of Annurca Apple Polyphenols on Hepatic Cells.

Sommella E, Badolati N, Riccio G, Salviati E, Bottone S, Dentice M, Campiglia P, Tenore GC, Stornaiuolo M, Novellino E.

Nutrients. 2019 Jan 14;11(1). pii: E163. doi: 10.3390/nu11010163.

2.

T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells.

Riccio G, Ricardo AR, Passariello M, Saraiva K, Rubino V, Cunnah P, Mertens N, De Lorenzo C.

J Immunother. 2019 Jan;42(1):1-10. doi: 10.1097/CJI.0000000000000248.

PMID:
30520849
3.

Annurca Apple Polyphenols Protect Murine Hair Follicles from Taxane Induced Dystrophy and Hijacks Polyunsaturated Fatty Acid Metabolism toward β-Oxidation.

Riccio G, Sommella E, Badolati N, Salviati E, Bottone S, Campiglia P, Dentice M, Tenore GC, Stornaiuolo M, Novellino E.

Nutrients. 2018 Nov 20;10(11). pii: E1808. doi: 10.3390/nu10111808.

4.

Annurca Apple Polyphenols Ignite Keratin Production in Hair Follicles by Inhibiting the Pentose Phosphate Pathway and Amino Acid Oxidation.

Badolati N, Sommella E, Riccio G, Salviati E, Heintz D, Bottone S, Di Cicco E, Dentice M, Tenore G, Campiglia P, Stornaiuolo M, Novellino E.

Nutrients. 2018 Oct 2;10(10). pii: E1406. doi: 10.3390/nu10101406.

5.

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.

De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N.

Onco Targets Ther. 2018 Apr 19;11:2241-2250. doi: 10.2147/OTT.S157294. eCollection 2018.

6.

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.

Riccio G, Antonucci S, Coppola C, D'Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N.

Front Physiol. 2018 Feb 6;9:38. doi: 10.3389/fphys.2018.00038. eCollection 2018.

7.

A Negative Allosteric Modulator of WNT Receptor Frizzled 4 Switches into an Allosteric Agonist.

Riccio G, Bottone S, La Regina G, Badolati N, Passacantilli S, Rossi GB, Accardo A, Dentice M, Silvestri R, Novellino E, Stornaiuolo M.

Biochemistry. 2018 Feb 6;57(5):839-851. doi: 10.1021/acs.biochem.7b01087. Epub 2018 Jan 19.

PMID:
29293331
8.

WNT Inhibitory Activity of Malus Pumila miller cv Annurca and Malus domestica cv Limoncella Apple Extracts on Human Colon-Rectal Cells Carrying Familial Adenomatous Polyposis Mutations.

Riccio G, Maisto M, Bottone S, Badolati N, Rossi GB, Tenore GC, Stornaiuolo M, Novellino E.

Nutrients. 2017 Nov 18;9(11). pii: E1262. doi: 10.3390/nu9111262.

9.

Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody.

Riccio G, Da Fonseca-Ricardo AR, Passariello M, Cunnah P, Mertens N, De Lorenzo C.

J Immunother. 2017 Jan 25. doi: 10.1097/CJI.0000000000000152. [Epub ahead of print]

PMID:
28125512
10.

Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking.

Coppola C, Riccio G, Barbieri A, Monti MG, Piscopo G, Rea D, Arra C, Maurea C, De Lorenzo C, Maurea N.

Onco Targets Ther. 2016 Nov 2;9:6785-6794. eCollection 2016.

11.

Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e19-e26. Review.

PMID:
27755239
12.

Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S19-26. doi: 10.2459/JCM.0000000000000377. Review.

PMID:
27183521
13.

WITHDRAWN:A Practical Approach for Management of QT Prolongation Induced by Anticancer Drugs.

Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, De Lorenzo C.

Oncologist. 2016 Mar 14. pii: theoncologist.2015-0313. [Epub ahead of print] Review.

14.

Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?

Riccio G, Coppola C, Piscopo G, Capasso I, Maurea C, Esposito E, De Lorenzo C, Maurea N.

Hum Vaccin Immunother. 2016 May 3;12(5):1124-31. doi: 10.1080/21645515.2015.1125056. Epub 2016 Feb 2.

15.

One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1.

Sasso E, Paciello R, D'Auria F, Riccio G, Froechlich G, Cortese R, Nicosia A, De Lorenzo C, Zambrano N.

Biomed Res Int. 2015;2015:703213. doi: 10.1155/2015/703213. Epub 2015 Nov 15.

16.

Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.

Paciello R, Urbanowicz RA, Riccio G, Sasso E, McClure CP, Zambrano N, Ball JK, Cortese R, Nicosia A, De Lorenzo C.

J Gen Virol. 2016 Jan;97(1):82-94. doi: 10.1099/jgv.0.000330. Epub 2015 Oct 29.

17.

Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

D'Avino C, Paciello R, Riccio G, Coppola C, Laccetti P, Maurea N, Raines RT, De Lorenzo C.

Protein Eng Des Sel. 2014 Mar;27(3):83-8. doi: 10.1093/protein/gzt065. Epub 2014 Jan 12. Erratum in: Protein Eng Des Sel. 2014 May;27(5):177. Coppola, Melina [corrected to Coppola, Carmela].

18.

Effects of a human compact anti-ErbB2 antibody on gastric cancer.

Fedele C, Carvalho S, Riccio G, Paciello R, Laccetti P, Schmitt F, De Lorenzo C.

Gastric Cancer. 2014 Jan;17(1):107-15. doi: 10.1007/s10120-013-0244-z. Epub 2013 Mar 5.

PMID:
23460348
19.

A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.

Riccio G, D'Avino C, Raines RT, De Lorenzo C.

Protein Eng Des Sel. 2013 Mar;26(3):243-8. doi: 10.1093/protein/gzs101. Epub 2012 Dec 11.

20.

Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.

Fedele C, Riccio G, Malara AE, D'Alessio G, De Lorenzo C.

Breast Cancer Res Treat. 2012 Jul;134(2):595-602. doi: 10.1007/s10549-012-2103-8. Epub 2012 Jun 7.

PMID:
22674190

Supplemental Content

Loading ...
Support Center